Eison A S, Wright R N
CNS Special Projects, Bristol-Myers Squibb Company, Wallingford, CT 06492.
Pharmacol Biochem Behav. 1992 Sep;43(1):131-7. doi: 10.1016/0091-3057(92)90649-z.
Although the ability of agonists at specific serotonin (5-HT) receptor subtypes to induce distinct behaviors has been well documented in the rat, similar studies have not been reported in the Mongolian gerbil. We have found that the 5-HT1A/5-HT2 agonist 5-methoxy,N-N dimethyltryptamine (5-MeODMT) (0.5-8 mg/kg, SC), the specific 5-HT1A agonist 8-hydroxy(di-n-propylamino)tetralin (8-OH-DPAT) (0.125-16 mg/kg, SC), and the 5-HT precursor L-5-hydroxytryptophan (L-5-HTP) (100-250 mg/kg, SC) all elicit a 5-HT syndrome in the gerbil. This syndrome, analogous to the 5-HT syndrome in the rat, consists of reciprocal forepaw treading (RFT), hindleg abduction (HA), body tremors (BT), and Straub tail (ST). The putative 5-HT1A antagonist NAN-190 (0.25-8 mg/kg, SC) when dosed 15 min prior to either 5-MeODMT (4 mg/kg, SC) or 8-OH-DPAT (16 mg/kg, SC) blocked both RFT and HA in a dose-dependent manner, suggesting these 5-HT syndrome behaviors are mediated via 5-HT1A receptor activation. We also identified a unique, dose-responsive behavior in the gerbil, induced selectively by 5-HT1A agonists such as quipazine (2-16 mg/kg, SC) and (+-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) (0.125-8 mg/kg, SC). This reciprocal hindleg body scratch (RHBS) behavior is dose dependently inhibited by pretreatment with the selective 5-HT2 antagonist ritanserin (0.0125-0.2 mg/kg, SC). RHBS behavior is also potently inhibited by pretreatment with the selective 5-HT1A agonist 8-OH-DPAT (0.005-0.04 mg/kg, SC), demonstrating a 5-HT1A/5-HT2 receptor subtype interaction.(ABSTRACT TRUNCATED AT 250 WORDS)
尽管特定血清素(5-羟色胺,5-HT)受体亚型的激动剂诱导大鼠产生不同行为的能力已有充分记录,但在蒙古沙鼠中尚未有类似研究报道。我们发现,5-HT1A/5-HT2激动剂5-甲氧基-N,N-二甲基色胺(5-MeODMT)(0.5 - 8毫克/千克,皮下注射)、特异性5-HT1A激动剂8-羟基(二正丙基氨基)四氢萘(8-OH-DPAT)(0.125 - 16毫克/千克,皮下注射)以及5-HT前体L-5-羟色氨酸(L-5-HTP)(100 - 250毫克/千克,皮下注射)均可在沙鼠中引发5-羟色胺综合征。该综合征类似于大鼠中的5-羟色胺综合征,包括前爪交互踏动(RFT)、后肢外展(HA)、身体震颤(BT)和施特劳布尾(ST)。在给予5-MeODMT(4毫克/千克,皮下注射)或8-OH-DPAT(16毫克/千克,皮下注射)前15分钟注射假定的5-HT1A拮抗剂NAN-190(0.25 - 8毫克/千克,皮下注射),可剂量依赖性地阻断RFT和HA,表明这些5-羟色胺综合征行为是通过5-HT1A受体激活介导的。我们还在沙鼠中发现了一种独特的、剂量反应性的行为,由5-HT1A激动剂如喹哌嗪(2 - 16毫克/千克,皮下注射)和(±)-1-(2,5-二甲氧基-4-碘苯基)-2-氨基丙烷(DOI)(0.125 - 8毫克/千克,皮下注射)选择性诱导。这种后肢交互身体抓挠(RHBS)行为可被选择性5-HT2拮抗剂利坦色林(0.0125 - 0.2毫克/千克,皮下注射)预处理剂量依赖性抑制。RHBS行为也可被选择性5-HT1A激动剂8-OH-DPAT(0.005 - 0.04毫克/千克,皮下注射)预处理有效抑制,表明存在5-HT1A/5-HT2受体亚型相互作用。(摘要截短于250字)